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Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent 
in rats
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The primary objective of this study was to compare the
pharmacokinetics of a new anti-human immunodeficiency
virus agent 1-(2-amino-pyridin-4-ylmethyl)-6-(3,5-dimethyl-
benzoyl)-5-isopropyl-1H-pyrimidine-2,4-dione (VP-0502)
with its amino acid prodrug alanine amide of VP-0502
(VP-0502AL), following intravenous and oral administrations
to rats. The plasma concentrations of both analytes were
analyzed  via high-performance liquid chromatography
coupled with photodiode-array detection (HPLC-DAD).
When VP-0502 was intravenously administered at 20 mg/
kg, the analyte appeared in low levels with an AUC of 0.3
µg · h/ml, and C0 of 0.2 µg/ml in plasma. However, both
the prodrug VP-0502AL and its metabolite VP-0502 appeared
at comparatively higher levels following intravenous
injection of VP-0502AL at the same dose. VP-0502AL’s
pharmacokinetic parameters were V d:  4.6 l/kg; AUC:
3 µg·h / m l ;  t 1/2: 0.5 h; C0: 6 µg/ml; CLtot: 7 l/h/kg; and
MRT: 0.6 h. Following oral administration of VP-0502
(100 mg/kg), it was not detectable in plasma (<50 ng/ml),
while after the oral administration of VP-0502AL, VP-
0502 was quantitatively detected as an active metabolite for
the first 7 h, with a maximum plasma concentration
(Cmax) of 0.8 µg/ml, and an area under the concentration-
time curve (AUC) of 2 µg · h/ml. The oral pharmacokinetic
parameters of VP-0502AL were calculated to be: maximum
concentration time (tmax) 2.7 h; Cmax 0.2 µg/ml; elimination
half-life (t1/2): 0.8 h; and AUC 0.5 µg · h/ml. Overall the
findings indicate that VP-0502AL has a favorable pharmaco-
kinetic profile as a prodrug with rapid transformation
into the active metabolite, and that the attachment of the
amino acid alanine to VP-0502 is an effective approach to
improve its oral bioavailability. VP-0502AL is predicted
to become a new highly bioavailable anti-AIDS drug
candidate and/or lead compound.
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Introduction
Since it was first discovered in California in 1981, AIDS
has been considered one of the worst diseases of mankind
that has been rapidly increasing around the world [7]. Anti-
human immunodeficiency virus (HIV) drugs can be divided
into several classes depending on their mechanism of action,
including the interception of the HIV inflow into immunocytes,
the inhibition of reproduction and proliferation within cells,
and the suppression of viral release from the cells after
reproduction. The development of non-nucleoside reverse
transcriptase inhibitors has also received much attention as
another class of HIV genome replication inhibitors [2,3,14].
However, this group of drugs often shows structural
hydrophobicity, and low solubility resulting in poor oral
bioavailability. For these reasons, there have been several
attempts to improve their oral bioavailability. We recently
developed a non-nucleoside reverse transcriptase inhibitor
1-(2-amino-pyridin-4-ylmethyl)-6-(3,5-dimethyl-benzoyl)-
5-isopropyl-1H-pyrimidine-2,4-dione (VP-0502) that is a
derivative of VP-0501 [4]. This compound however has a
very poor absorption profile after oral administration. For
this reason, we designed an amino acid-attached prodrug of
VP-0502 by binding the amino acid alanine to improve its
oral bioavailability. This paper describes a pharmacokinetic
comparison between VP-0502 and its prodrug alanine
amide of VP-0502 (VP-0502AL). This could lead to the





5-isopropyl-1H-pyrimidine-2,4-dione (VP-0502) and alanine
amide of VP-0502 (VP-0502AL) (Fig. 1, purity >96%) were
investigated in this study. Healthy, male rats (Sprague-
Dawley) of approximately 8 weeks old and weighing from
220 to 280 g (Orient, Korea) were used in this experiment.
The animals were determined to be healthy on the basis of
clinical examination. They were held under semi-barrier
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conditions at a constant 12 h cycle of light and dark, were
fed on a laboratory rodent diet (Pico 5053; Labdiet, Korea)
and had free access to drinking water throughout the
experimental period.
Drug preparation and administration
Animals were fasted for approximately 12 h prior to
dosing. For the intravenous bolus study, VP-0502 and VP-
0502AL were dissolved in 40% polyethylene glycol 400
(Fluka, USA) and injected via the tail vein at a dosage of 20
mg/5 ml/kg b.w. For the oral study, VP-0502 and VP-
0502AL were suspended in 14.3% citric acid (Duksan,
Korea) which was administered at a dosage of 100 mg/10
ml/kg. A syringe fitted with a stomach tube was used for the
oral administration. Each animal was weighed just before
drug treatment to ensure that the precise dose was given.
Blood sampling
200 µl blood samples were collected from the tail vein
using a vacutainer (Becton-Dickinson, USA) into a plastic
tube containing EDTA as an anticoagulant (final concentration
0.2%). Serial samples were obtained at the following times
after dosing: (i) In the intravenous study, pre-dosing (0), 0.5,
1, 2, 4, 6 and 8 h. (ii) In the oral study, pre-dosing, 0.5, 1, 2,
3, 4, 5, 6, 7 and 8 h. Immediately after collection, the blood
samples were gently inverted and placed on ice. The samples
were then centrifuged at 16,700 g (Hanil Microspin, Korea)
for 5 min and the plasma was recovered and maintained
frozen at −20
oC until analyzed within 2 weeks of sampling.
Frozen plasma samples were thawed at room temperature
prior to extraction, and each aliquot was mixed with three
volumes of methanol and vortexed (Thermolyne, USA).
The resulting mixture was centrifuged at 12,000 rpm for 2
min, and the supernatant was injected directly onto the high-
performance liquid chromatography (HPLC) column.
Drug analysis
A microbore HPLC system including a photodiode array
UV detector (Agilent, USA), a pump (Agilent, USA), a
degasser (Agilent, USA), an autosampler (Agilent, USA),
and a column oven (Agilent, USA) was used to measure
both VP-0502 and VP-0502AL in rat plasma. The analytical
column was a Capcell-pak C18 column (UG120, 100 × 2.0
mm I.D., 5 µm; Shiseido, Japan). The optimal mobile phase
conditions for both analytes were selected using an acetonitrile-
or methanol-water gradient system and the UV wavelength
was set at 264 nm. The mobile phase was a mixture of
0.01 M dibasic potassium phosphate (Sigma, USA) and
acetonitrile (60 : 40, v/v). The flow rate was 0.2 ml/min and
the column-oven temperature was set at 25
oC. The injection
volume was 5 µl. The stability of the compounds in rat
plasma was also studied over two weeks of sampling.
Pharmacokinetics
The pharmacokinetic parameters were obtained using a
pharmacokinetic program “WinNonlin”, fitting data to a
one-compartment open model. For the intravenous injection,
the pharmacokinetic parameters including elimination rate
constant (kel), distribution volume (Vd), elimination half-life
(t1/2), concentration right after administration (C 0), total
body clearance (CLtot), area under the concentration-time
curve (AUC), area under the moment curve (AUMC), and
the mean residence time (MRT) were estimated from the
model interpretation. The formula for the concentration in
plasma for intravenous injection was C(t) = D/V d · exp
-kel · t,
where C is the plasma concentration and D is the dose. For
the oral administration study, the lag time was considered
and the absorption and elimination rates were applied as
first-order kinetics. Model-dependent parameters including
the lag time (tlag), absorption rate constant (ka) and kel,
absorption half-time (t1/2,a) and t1/2, the time to reach the
maximum concentration (tmax), maximum concentration
(Cmax), and AUC were calculated. Bioavailability (F) was
calculated from the equation of F(%) = (AUC po/AUCiv)·
(Div/Dpo). The formula for oral administration was C(t) = D ·
ka/Vd/(ka-kel) · (exp
-kel · t-exp
-ka · t). Plasma drug concentrations
and the estimated pharmacokinetic parameters were reported
as mean ± SD (n = >3).
Results
Clinical observation
No particular clinical findings were observed after
administration of VP-0502 and VP-0502AL by either route
to rats.
Drug analysis
The chromatograms of both analytes, VP-0502 and VP-
0502AL, are shown in Fig. 2. The UV wavelength was set at
264 nm based on the λ max value from the result of UV
spectra scanning. Under these conditions, VP-0502 and VP-
0502AL were separated well on the chromatogram and were
eluted within 10 min. The recoveries of VP-0502 and VP-
0502AL were 77% and 87%, respectively. The limits of
quantification (LOQ) were lower than 50 ng/ml for both
analytes.
Fig. 1. Structure of alanine amide (AL) of 1-(2-amino-pyridin-4-
ylmethyl)-6-(3,5-dimethyl-benzoyl)-5-isopropyl-1H-pyrimidine-
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Pharmacokinetics
VP-0502 was not detected in the plasma following oral
administration to rats at a dose rate of 100 mg/kg. However,
it was readily found in the plasma following intravenous
injection at a dose of 20 mg/kg, though the plasma
concentration level was minimal (Fig. 3). Table 1 shows the
pharmacokinetic parameters of VP-0502 injected intravenously,
where the AUC, t1/2, C 0, CLtot, AUMC, and MRT were
0.3 µg · h/ml, 1.6 h, 0.2 µg/ml, 69 l/h/kg, 0.7 µg · h
2/ml and
2 h, respectively.
When VP-0502AL was orally administered, both VP-
0502 and VP-0502AL were quantitatively observed in
plasma as shown in Fig. 3. The pharmacokinetic parameters
of VP-0502AL including tlag, tmax, Cmax, t1/2, F and AUC
were 1.6 h, 2.7 h, 0.2 µg/ml, 1 h, 3.4% and 0.5 µg · h/ml,
respectively (Table 2). Moreover, the active metabolite (VP-
0502) was found in the plasma at significantly higher levels
than the parent compound (VP-0502AL) with C max of 0.8
µg/ml and AUC of 2 µg · h/ml (Fig. 4). When VP-0502AL
Fig. 2. Chromatograms of VP-0502 and VP-0502AL detected in
rat plasma following oral administration of VP-0502AL at a dose
of 100 mg/kg.
Fig. 3. Semilogarithmic graph depicting the plasma concentratio n
time curve of VP-0502 following intravenous administration.
Table 1. Pharmacokinetic parameters of VP-0502 after intravenous
administration of 20 mg/kg to rats
Parameters (units) Mean ± SD
kel (h
-1) 0.549 ± 0.352
t1/2 (h) 1.615 ± 0.863
C0 (µg/ml) 0.202 ± 0.182
Vd (l/kg) 183.7 ± 163.1
CLtot (l/h/kg) 68.96 ± 30.03
AUC (µg · h/ml) 0.324 ± 0.119
AUMC (µg · h
2/ml) 0.659 ± 0.195
MRT (h) 2.330 ± 1.245
Footnote: kel (elimination rate constant), V d (distribution volume), t 1/2
(elimination half-life), C 0 (concentration right after administration), CL tot
(total body clearance), AUC (area under the concentration-time curve),
AUMC (area under the moment curve), and MRT (the mean residence
time).
Table 2. Pharmacokinetic parameters of VP-0502AL after oral
administration of 100 mg/kg to rats
Parameters (units) Mean ± SD
ka (h
-1) 1.117 ± 0.515
kel (h
-1) 1.110 ± 0.530
tlag (h) 1.582 ± 0.757
tmax (h) 2.682 ± 0.745
Cmax (µg/ml) 0.192 ± 0.123
t1/2,a (h) 0.753 ± 0.306
t1/2 (h) 0.772 ± 0.331
Vd/F (l/kg) 280.1 ± 460.1
CLtot/F (l/h/kg) 251.5 ± 516.5
AUC (µg · h/ml) 0.508 ± 0.352
Footnote: kel (elimination rate constant), V d (distribution volume), t 1/2
(elimination half-life), C 0 (concentration right after administration), CL tot
(total body clearance), AUC (area under the concentration-time curve),
tlag (lag time), ka (absorption rate constant), t 1/2,a (absorption half-time),
tmax (the time to reach the maximum concentration), C max (maximum
concentration).
Fig. 4. Semilogarithmic graph depicting the plasma concentratio n
time curves of VP-0502 (○) and VP-0502AL (●) following
oral administration of VP-0502AL.266 Kyung-Ae Chae et al.
was intravenously injected, both VP-0502 and VP-0502AL
appeared extensively in plasma as shown in Fig. 5. The
pharmacokinetics parameters of VP-0502AL were Vd: 5 l/
kg, AUC: 3 µg · h/ml, t1/2: 0.5 h, C0: 6 µg/ml, CLtot: 7 l/h/kg,
and AUMC: 2 µg·h
2/ml (Table 3).
Discussion
We performed a pharmacokinetic study of VP-0502 and
its prodrug VP-0502AL after oral and intravenous administration
to rats. No particular clinical changes were observed in any
of the treated animals. This indicates that a single dose (100
mg/kg orally or 20 mg/kg intravenously) of either drug did
not generate any visible clinical side effects in rats.
For the determination of VP-0502 and VP-0502AL in the
plasma, we developed an analytical HPLC system using
photodiode-array detection. Both VP-0502 and VP-0502AL
were successfully separated on the chromatogram within a
10 min retention time with no interceptive peak at the
selected 264 nm wavelengths. For the mobile phase, the
optimal conditions were obtained from a mixture of
phosphate buffer solution (K2HPO4, pH 7) and acetonitrile
(60 : 40, v/v). The ODS column was selected over the others
(C18, C8 and phenyl bonded), because it revealed excellent
resolution properties. The LOQs and recoveries were found
to be sufficient to detect both analytes in the plasma
samples. Therefore, the current HPLC system is considered
an appropriate technique for simple and rapid determination
of the VP-compounds for pharmacokinetic analyses in rats.
Following oral administration of VP-0502, the analyte
was not detectable in the plasma, but it was readily detected
following the intravenous injection. This indicates that the
bioavailability of VP-0502 is negligible and thus its application
in practice has no significance in terms of its poor oral
pharmacokinetic profiles. It is therefore necessary to develop
a drug delivery system (DDS) in order to improve the
bioavailability of VP-0502. Accordingly, an amino acid
formula (pro-drug VP-0502AL) was designed for this study.
This type of amino acid-attached DDS not only increases
the solubility but also it improves its pharmacokinetic
profile [1]. For instance, when L-glutamic acid was added to
the formula, the receptivity went up and the drug could be
effectively delivered to a target [15]. Furthermore, many
research works attempt to improve the oral absorption of
poor-soluble drugs by increasing the solubility for which
amino acid attachment is considered. Thus, structures have
been developed that increase the receptivity via combination
with one to three amino acids, enable the transformation of
the pro-drug to active metabolite, which targets the
hydrolases of digestive mucosa, [5,6,8-13,16].
Although VP-0502 was not detected in plasma when
administered orally, both the parent compound VP-0502AL
and its active metabolite VP-0502, simultaneously appeared
in the plasma following the oral administration of VP-
0502AL, with significant Cmax of 0.8 µg/ml and an AUC of
2µg ·h/ml. Furthermore, the VP-compounds were maintained in
the plasma for over 7 h. This result shows that the
bioavailability of VP-0502 when administered as an amino
acid–attached pro-drug was notably increased. Data
collected after oral administration of VP-0502AL were best
fitted to a one-compartment open model with the first-order
output. The approximate time to reach the maximum
concentration was about 3 h and the maximum plasma
concentration was 0.2 µg/ml. The elimination half-life was
about 1 h, and the area under the plasma concentration-time
curve of 0.5 µg · h/ml was sufficiently to suggest the efficiency
of the prodrug, compared to VP-0502. Additionally, in terms
of pharmacokinetics, rapid oral absorption and transformation
to an active form, and the maintenance of concentration in
plasma were satisfactory for a new prodrug candidate. The
improvement of bioavailability by the amino acid alanine
formula for VP-0501AL performed prior to this, has shown
Fig. 5. Semilogarithmic graph depicting the plasma concentratio n
time curves of VP-0502 (○) and VP-0502AL (●) following
intravenous administration of VP-0502AL.
Table 3. Pharmacokinetic parameters of VP-0502AL after
intravenous administration of 20 mg/kg to rats
Parameters (units) Mean ± SD
kel (h
-1) 1.923 ± 1.030
t1/2 (h) 0.447 ± 0.254
C0 (µg/ml) 6.068 ± 4.312
Vd (l/kg) 4.641 ± 3.074
CLtot (l/h/kg) 6.871 ± 1.163
AUC (µg · h/ml) 2.974 ± 0.558
AUMC (µg · h
2/ml) 1.815 ± 0.838
MRT (h) 0.644 ± 0.366
Footnote: kel (elimination rate constant), V d (distribution volume), t 1/2
(elimination half-life), C 0 (concentration right after administration), CL tot
(total body clearance), AUC (area under the concentration-time curve),
AUMC (area under the moment curve), MRT (the mean residence time).Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats 267
a similar result to this test [4]. This confirmed that amino
acid alanine attachment is very effective approach to making
a prodrug. Therefore, VP-0502AL is expected to become a
highly bioavailable anti-AIDS drug candidate and/or lead
compound.
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